reference/31732130

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/31732130

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, Non-U.S. Gov't
endingPage	124
issn	1573-7373 0167-594X
issueIdentifier	1
pageRange	117-124
publicationName	Journal of Neuro-Oncology
startingPage	117
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_a00fabcde302d63a76ef3eae515fd4ec
bibliographicCitation	Morris KA, Golding JF, Blesing C, Evans DG, Ferner RE, Foweraker K, Halliday D, Jena R, McBain C, McCabe MG, Swampillai A, Warner N, Wilson S, Parry A, Afridi SK, On behalf of the UK NF2 research group. Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort. Journal of Neuro-Oncology. 2016 Oct 28;131(1):117–24. doi: 10.1007/s11060-016-2276-9.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3ce4a1cc6d828ddf98777076d2d40f0c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d92b812cef44c476ff1a4b00ce595c31 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5aad038cf8358c10cb0b631c543fa562 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2782b1a887047e190fc40b8e19304558 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_001c4fee6b3e9691cfea7ff82b11e2b0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dc2b03e3811c5da4e4e59c636a36a5a4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-5138-0707 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_35afb1192cca4ba938e70f940be6d215 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7aae7ee9c49c8b173d4bbd1c25f28a59 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0f3331bfa2ee52c0efc54c156d1a5140 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fdeb6acf46ce2a543cb182a288fb7873 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-8482-5784 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ce05d13fd7b12040d4f78c3b8e1066be http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_47c23ef5ae4dfba2b0fe2e567f29f875 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fd80ddcfbc0b13954ed02aaef61174f5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-1075-8424 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_03ce635f7262d3b9eb5cfacaf2a340f6
date	2016-10-28^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/27796735 https://doi.org/10.1007/s11060-016-2276-9
isPartOf	https://portal.issn.org/resource/ISSN/1573-7373 https://portal.issn.org/resource/ISSN/0167-594X http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5024
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://scigraph.springernature.com/ https://www.crossref.org/
title	Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort
discusses	http://id.nlm.nih.gov/mesh/M000626416 http://id.nlm.nih.gov/mesh/M0443627
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D016518Q000188 http://id.nlm.nih.gov/mesh/D000068258Q000009 http://id.nlm.nih.gov/mesh/D000074322Q000009 http://id.nlm.nih.gov/mesh/D009442Q000188 http://id.nlm.nih.gov/mesh/D006973Q000139 http://id.nlm.nih.gov/mesh/D006333Q000139
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D016518Q000150 http://id.nlm.nih.gov/mesh/D000293 http://id.nlm.nih.gov/mesh/D015331 http://id.nlm.nih.gov/mesh/D012044 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D055815 http://id.nlm.nih.gov/mesh/D009442Q000150 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D002648 http://id.nlm.nih.gov/mesh/D006113
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8989 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7922 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8167 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8102 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7181 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8643 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9878

Showing number of triples: 1 to 70 of 70.